Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Hammers on the CheckMate-214 Study for RCC

December 6th 2017

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the CheckMate-214 study for patients with renal cell carcinoma (RCC).

Dr. Jonasch on Sequencing Challenges in RCC

December 5th 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses sequencing challenges facing patients with renal cell carcinoma (RCC).

Neoadjuvant Chemotherapy Significantly Improves OS for Low-Risk, Basal Bladder Cancer

December 2nd 2017

Treatment with neoadjuvant chemotherapy prior to radical cystectomy significantly improved overall survival compared with cystectomy alone for patients with the basal subtype of muscle-invasive bladder cancer.

Dr. Voss Discusses Neoadjuvant Trials of Immunotherapy in RCC

December 1st 2017

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neoadjuvant immunotherapy trials in renal cell carcinoma (RCC).

Dr. Apolo on Managing Toxicities With Checkpoint Inhibitors in Bladder Cancer

December 1st 2017

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing toxicities with checkpoint inhibitors in bladder cancer.

Checkpoint Inhibitors Hold Promise for BCG-Unresponsive NMIBC

December 1st 2017

The established efficacy of single-agent checkpoint inhibition for metastatic urothelial carcinoma along with molecule expression analyses suggests that PD-1/PD-L1 inhibition could hold promise for patients with non-muscle invasive bladder cancer, particularly those unresponsive to Bacillus Calmette-Guérin.

Dr. Sonpavde Discusses Current Clinical Trials in Penile Cancer

December 1st 2017

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses current clinical trials in penile cancer.

Dr. Hammers Discusses Combining IDO and PD-1 Inhibitors in RCC

December 1st 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the potential combination of IDO inhibitors and PD-1 inhibitors in renal cell carcinoma.

Dr. Harrison on Choosing Frontline Treatment for RCC

December 1st 2017

Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses choosing frontline treatment for patients with renal cell carcinoma (RCC).

Plimack Recaps 2017 Immunotherapy Approvals in Bladder Cancer

December 1st 2017

It has been a landmark year for immunotherapy in bladder cancer with the approval of 5 checkpoint inhibitors across first and second line.

Immunotherapy Combinations on the Rise for RCC

November 30th 2017

The combination of PD-1 or PD-L1 inhibitors with existing frontline therapies could represent a superior approach for some treatment-naïve patients with renal cell carcinoma.

Plethora of Ongoing Trials Explore Immunotherapy Combinations for Bladder Cancer

November 30th 2017

Stemming from the wave of checkpoint inhibitor approvals, multiple trials have begun evaluating immunotherapies in combination with other agents for the treatment of patients with advanced bladder cancer.

Dr. Plimack on Frontline Checkpoint Inhibitors in Bladder Cancer

November 30th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses checkpoint inhibitors in the frontline setting of bladder cancer.

Dr. McDermott on Nivolumab Plus Ipilimumab in RCC

November 30th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in renal cell carcinoma (RCC).

Immunotherapy Combo Regimens Next Step in Bladder Cancer

November 30th 2017

Elizabeth Plimack, MD, discusses the impact of the immunotherapy approvals in the first- and second-line setting for bladder cancer and the future of combinations for these patients.

Dr. Friedlander on Checkpoint Inhibitors in the Second-Line Setting of Bladder Cancer

November 30th 2017

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in the second-line setting for patients with bladder cancer.

Future of Bladder Cancer Care to Include Immunotherapy Combos

November 29th 2017

Petros Grivas, MD, shares insight on the value of combining immunotherapy regimens in the treatment of patients with urothelial carcinoma.

Agarwal Recaps Advancements in Newly Diagnosed RCC

November 27th 2017

Neeraj Agarwal, MD, recaps the latest advancements in newly diagnosed RCC.

Dr. Holzbeierlein on the Management of Bladder Cancer Guidelines

November 23rd 2017

Jeffrey M. Holzbeierlein, MD, professor, director of Urologic Oncology, Department of Urology, University of Kansas Medical Center, discusses the management guidelines for patients with bladder cancer.

Dr. Jonasch on the CABOSUN Trial in RCC

November 22nd 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the CABOSUN study in renal cell carcinoma (RCC).